NICE terminates sixth health technology appraisal in light of lack of evidence
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has terminated its appraisal of Amgen's Prolia (denosumab) for treating therapy-induced bone loss in people with non-metastatic prostate cancer. This marks the sixth time that the institute has ended an appraisal because of a lack of evidence from the manufacturer.